<?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName journalpublishing.dtd?>
<?SourceDTD.Version 2.3?>
<?ConverterInfo.XSLTName nlm2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Front Genet</journal-id>
    <journal-id journal-id-type="iso-abbrev">Front Genet</journal-id>
    <journal-id journal-id-type="publisher-id">Front. Genet.</journal-id>
    <journal-title-group>
      <journal-title>Frontiers in Genetics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1664-8021</issn>
    <publisher>
      <publisher-name>Frontiers Media S.A.</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9197487</article-id>
    <article-id pub-id-type="publisher-id">868015</article-id>
    <article-id pub-id-type="doi">10.3389/fgene.2022.868015</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Genetics</subject>
        <subj-group>
          <subject>Original Research</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit</article-title>
      <alt-title alt-title-type="left-running-head">Lee et al.</alt-title>
      <alt-title alt-title-type="right-running-head">StarGazer: Hybrid Intelligence Target Discovery</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Lee</surname>
          <given-names>Chiyun</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="fn1" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1661478/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Junxia</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="fn1" ref-type="author-notes">
          <sup>†</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1661503/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Prokop</surname>
          <given-names>Andrzej</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gopalakrishnan</surname>
          <given-names>Vancheswaran</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>4</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1646106/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hanna</surname>
          <given-names>Richard N.</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">
          <sup>5</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Papa</surname>
          <given-names>Eliseo</given-names>
        </name>
        <xref rid="aff6" ref-type="aff">
          <sup>6</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Freeman</surname>
          <given-names>Adrian</given-names>
        </name>
        <xref rid="aff7" ref-type="aff">
          <sup>7</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1760130/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Patel</surname>
          <given-names>Saleha</given-names>
        </name>
        <xref rid="aff7" ref-type="aff">
          <sup>7</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Yu</surname>
          <given-names>Wen</given-names>
        </name>
        <xref rid="aff8" ref-type="aff">
          <sup>8</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huhn</surname>
          <given-names>Monika</given-names>
        </name>
        <xref rid="aff9" ref-type="aff">
          <sup>9</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sheikh</surname>
          <given-names>Abdul-Saboor</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tan</surname>
          <given-names>Keith</given-names>
        </name>
        <xref rid="aff10" ref-type="aff">
          <sup>10</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sellman</surname>
          <given-names>Bret R.</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>4</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/1682305/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cohen</surname>
          <given-names>Taylor</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>4</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/972049/overview"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mangion</surname>
          <given-names>Jonathan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Khan</surname>
          <given-names>Faisal M.</given-names>
        </name>
        <xref rid="aff8" ref-type="aff">
          <sup>8</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gusev</surname>
          <given-names>Yuriy</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>2</sup>
        </xref>
        <uri xlink:href="https://loop.frontiersin.org/people/107779/overview"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Shameer</surname>
          <given-names>Khader</given-names>
        </name>
        <xref rid="aff8" ref-type="aff">
          <sup>8</sup>
        </xref>
        <xref rid="c001" ref-type="corresp">*</xref>
        <uri xlink:href="https://loop.frontiersin.org/people/470550/overview"/>
      </contrib>
    </contrib-group>
    <aff id="aff1"><sup>1</sup><institution>Data Science and Artificial Intelligence, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Cambridge</addr-line>, <country>United Kingdom</country></aff>
    <aff id="aff2"><sup>2</sup><institution>Georgetown University</institution>, <addr-line>Washington</addr-line>, <addr-line>DC</addr-line>, <country>United States</country></aff>
    <aff id="aff3"><sup>3</sup><institution>Biometrics, Oncology R&amp;D, AstraZeneca</institution>, <addr-line>Warsaw</addr-line>, <country>Poland</country></aff>
    <aff id="aff4"><sup>4</sup><institution>Discovery Microbiome, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Gaithersburg</addr-line>, <addr-line>MD</addr-line>, <country>United States</country></aff>
    <aff id="aff5"><sup>5</sup><institution>Early Respiratory and Immunology, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Gaithersburg</addr-line>, <addr-line>MD</addr-line>, <country>United States</country></aff>
    <aff id="aff6"><sup>6</sup><institution>Research Data and Analytics, R&amp;D IT, AstraZeneca</institution>, <addr-line>Cambridge</addr-line>, <country>United Kingdom</country></aff>
    <aff id="aff7"><sup>7</sup><institution>Discovery Sciences, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Cambridge</addr-line>, <country>United Kingdom</country></aff>
    <aff id="aff8"><sup>8</sup><institution>Data Science and Artificial Intelligence, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Gaithersburg</addr-line>, <addr-line>MD</addr-line>, <country>United States</country></aff>
    <aff id="aff9"><sup>9</sup><institution>Biometrics and Information Sciences, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Mölndal</addr-line>, <country>Sweden</country></aff>
    <aff id="aff10"><sup>10</sup><institution>Neuroscience, BioPharmaceuticals R&amp;D, AstraZeneca</institution>, <addr-line>Cambridge</addr-line>, <country>United Kingdom</country></aff>
    <author-notes>
      <fn fn-type="edited-by">
        <p><bold>Edited by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/337598/overview" ext-link-type="uri">Rinku Sharma</ext-link>, Harvard Medical School, United States</p>
      </fn>
      <fn fn-type="edited-by">
        <p><bold>Reviewed by:</bold><ext-link xlink:href="https://loop.frontiersin.org/people/388702/overview" ext-link-type="uri">Rajesh Kumar Pathak</ext-link>, Chung-Ang University, South Korea</p>
        <p><ext-link xlink:href="https://loop.frontiersin.org/people/1341998/overview" ext-link-type="uri">Sezen Vatansever</ext-link>, Icahn School of Medicine at Mount Sinai, United States</p>
      </fn>
      <corresp id="c001">*Correspondence: Khader Shameer, <email>shameer.khader@astrazeneca.com</email>
</corresp>
      <fn fn-type="equal" id="fn1">
        <label>
          <sup>†</sup>
        </label>
        <p>These authors contributed equally to this work</p>
      </fn>
      <fn fn-type="other">
        <p>This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>31</day>
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>13</volume>
    <elocation-id>868015</elocation-id>
    <history>
      <date date-type="received">
        <day>01</day>
        <month>2</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>29</day>
        <month>4</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 Lee, Lin, Prokop, Gopalakrishnan, Hanna, Papa, Freeman, Patel, Yu, Huhn, Sheikh, Tan, Sellman, Cohen, Mangion, Khan, Gusev and Shameer.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Lee, Lin, Prokop, Gopalakrishnan, Hanna, Papa, Freeman, Patel, Yu, Huhn, Sheikh, Tan, Sellman, Cohen, Mangion, Khan, Gusev and Shameer</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
      </license>
    </permissions>
    <abstract>
      <p>Target prioritization is essential for drug discovery and repositioning. Applying computational methods to analyze and process multi-omics data to find new drug targets is a practical approach for achieving this. Despite an increasing number of methods for generating datasets such as genomics, phenomics, and proteomics, attempts to integrate and mine such datasets remain limited in scope. Developing hybrid intelligence solutions that combine human intelligence in the scientific domain and disease biology with the ability to mine multiple databases simultaneously may help augment drug target discovery and identify novel drug-indication associations. We believe that integrating different data sources using a singular numerical scoring system in a hybrid intelligent framework could help to bridge these different omics layers and facilitate rapid drug target prioritization for studies in drug discovery, development or repositioning. Herein, we describe our prototype of the StarGazer pipeline which combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer displays target prioritization scores for genes associated with 1844 phenotypic traits, and is available via <ext-link xlink:href="https://github.com/AstraZeneca/StarGazer" ext-link-type="uri">https://github.com/AstraZeneca/StarGazer</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>multi-omics</kwd>
      <kwd>target prioritization</kwd>
      <kwd>drug discovery</kwd>
      <kwd>repositioning</kwd>
      <kwd>data integration</kwd>
      <kwd>streamlit</kwd>
      <kwd>stargazer</kwd>
      <kwd>hybrid intelligence</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="s1">
    <title>Introduction</title>
    <p>Drug repositioning has been rapidly gaining attention in the drug discovery domain during the past decade (<xref rid="B67" ref-type="bibr">Xue et al., 2018</xref>). Drug repositioning/repurposing describes the act of identifying alternative uses for a drug beyond the scope of its original indication, regardless of whether it has been FDA-approved or has failed in clinical trials (<xref rid="B45" ref-type="bibr">Pushpakom et al., 2019</xref>). The reasons for investing into drug repositioning are very numerous indeed.</p>
    <p>Traditionally, a standard drug development cycle is estimated to take around 10 years and requires billions of dollars of investment, notwithstanding the still disappointingly high failure rate at clinical trials (<xref rid="B35" ref-type="bibr">Li et al., 2016</xref>). In light of these problems, drug repositioning holds potential to drastically reduce the time and money needed to bring a drug to the market: it has been estimated to reduce the time by half and cut costs by 5-fold when compared to developing a new drug from scratch (<xref rid="B56" ref-type="bibr">Shameer et al., 2015</xref>). These factors alone highlight the appealing opportunity to bring medicines to patients faster, and potentially into areas of unmet therapeutic demand. Moreover, it allows for the existing arsenal of approved drugs to be more broadly utilized, and for the opportunity to salvage some costs involved in the development of drugs that failed in clinical trials. Finally, the sheer variety in successful and promising repositioning strategies to date speaks to the potential for unearthing profound biological links between different diseases, driving paradigm shifts in our approach to modern medicine (<xref rid="B33" ref-type="bibr">Lee and Bhakta, 2021</xref>).</p>
    <p>Drug target prioritization is an essential step for repositioning as it aims to highlight the potential drug targets for a particular disease. Applying computational methods to analyze and process multi-omics data is an effective approach for achieving this (<xref rid="B5" ref-type="bibr">Ashburn and Thor, 2004</xref>; <xref rid="B24" ref-type="bibr">Glicksberg et al., 2014</xref>; <xref rid="B54" ref-type="bibr">Shameer et al., 2018a</xref>; <xref rid="B45" ref-type="bibr">Pushpakom et al., 2019</xref>; <xref rid="B25" ref-type="bibr">Guo et al., 2021</xref>; <xref rid="B46" ref-type="bibr">Rapicavoli et al., 2022</xref>). Whilst there is now a vast wealth of biochemical and biomedical data in the current era of high-throughput omics technology, our ability to integrate and interpret these data has lagged behind and is presenting a great challenge in disease biology (<xref rid="B56" ref-type="bibr">Shameer et al., 2015</xref>). While machine learning approaches are generally used to develop tools to integrate, analyze and interpret multi-omics data, it remains a challenge that mere automation of predicting biological insights might overrepresent hypotheses that cannot be validated using function test experiments (<xref rid="B27" ref-type="bibr">Hodos et al., 2016</xref>; <xref rid="B43" ref-type="bibr">Peters et al., 2017</xref>). In such a scenario, we recommend the application of a hybrid intelligence platform that enables visual intelligence, quick search, contextual interpretations with quantitative approaches as a way to address this problem. Hybrid intelligence systems have been developed to address challenging problems in biomedicine, including remote patient diagnosis (<xref rid="B1" ref-type="bibr">Abu-Doleh et al., 2012</xref>; <xref rid="B36" ref-type="bibr">Li et al., 2014a</xref>; <xref rid="B3" ref-type="bibr">Akata et al., 2020</xref>; <xref rid="B25" ref-type="bibr">Guo et al., 2021</xref>; <xref rid="B65" ref-type="bibr">Weissler et al., 2021</xref>). However, such approaches are not readily available to address challenges in data integration and mining associated with drug target prioritization and drug repositioning.</p>
    <p>Data from genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS) have been used for drug target prioritization (<xref rid="B20" ref-type="bibr">Ferrero and Agarwal, 2018</xref>). Whilst GWAS aim to identify associations between genetic variants with a single phenotype, PheWAS interrogate numerous phenotypic traits at once (<xref rid="B18" ref-type="bibr">Denny et al., 2010</xref>). As of 06 October 2021, the EMBL-EBI GWAS catalog collates associations from 5,370 studies that, in total, identified more than 290,000 associations. The utility of this GWAS dataset can be further amplified by narrowing down the genes of interest to only those with known drug indications (<xref rid="B51" ref-type="bibr">Sanseau et al., 2012</xref>). Importantly, a three-step strategy for drug repositioning using PheWAS data has already been proposed (<xref rid="B47" ref-type="bibr">Rastegar-Mojarad et al., 2015</xref>): (<xref rid="B67" ref-type="bibr">Xue et al., 2018</xref>)—identify all genes with known associations with the phenotypic trait of interest using PheWAS data; (<xref rid="B45" ref-type="bibr">Pushpakom et al., 2019</xref>);—identify all drugs with associations with the previously identified genes using data from DrugBank; and (<xref rid="B35" ref-type="bibr">Li et al., 2016</xref>)—return all the drugs identified in the previous step as candidates for repositioning for the original phenotypic trait of interest. Others have gone further by incorporating a combination of data from GWASs (<xref rid="B30" ref-type="bibr">Khosravi et al., 2019</xref>), expression profile analysis (<xref rid="B32" ref-type="bibr">Lau and So, 2020</xref>), functional annotation, biological network analysis, and gene-set association (<xref rid="B48" ref-type="bibr">Reay and Cairns, 2021</xref>).</p>
    <p>Taken together, these data highlight the potential of using GWAS and PheWAS data for drug target prioritization. However, the field is still young, and integrating disparate data sources remains relatively limited in scope (<xref rid="B21" ref-type="bibr">Gallo et al., 2021</xref>). We hypothesize that integrating multimodal data sources using a singular numerical scoring system could accelerate the discovery and prioritization of drug targets. In light of this, we present our interactive dashboard, StarGazer, which aims to address these challenges by integrating three different datatypes (i.e., disease-target association, target druggability, and target protein-protein interaction) into a novel scoring system, utilizing real-time API calls and Python-based Streamlit technology. While these types of datasets have been used for numerous repositioning studies separately (<xref rid="B37" ref-type="bibr">Liu et al., 2014</xref>; <xref rid="B29" ref-type="bibr">Khaladkar et al., 2017</xref>; <xref rid="B26" ref-type="bibr">Hermawan et al., 2020</xref>; <xref rid="B66" ref-type="bibr">Wijetunga et al., 2020</xref>; <xref rid="B2" ref-type="bibr">Adikusuma et al., 2021</xref>; <xref rid="B6" ref-type="bibr">Attique et al., 2021</xref>; <xref rid="B23" ref-type="bibr">Ghoussaini et al., 2021</xref>; <xref rid="B44" ref-type="bibr">Portelli et al., 2021</xref>; <xref rid="B62" ref-type="bibr">Tan et al., 2021</xref>; <xref rid="B63" ref-type="bibr">Varghese and Majumdar, 2022</xref>; <xref rid="B69" ref-type="bibr">Zhao et al., 2022</xref>), StarGazer represents the first ever integration of the PheWAS catalog, Open Targets, STRING and Pharos, all of which are well-curated, well-studied, open access databases. Furthermore, computational repositioning studies focus largely on singular diseases, phenotypes or drugs, but StarGazer is equipped for flexible investigation into any of the 1,844 phenotypes and traits within the dashboard. Much of the data is up-to-date with the latest science, as it is loaded in real-time before it is analyzed in real time. StarGazer’s drug target prioritization mode allows for rapid identification of potential drug targets for a disease of interest, also providing immediate analysis of various aspects surrounding drug development, such as druggability and the nature of the target-disease association. In addition to this target prioritization feature, we anticipate that StarGazer’s ability to display all phenotypes associated with genes or gene variants of interest in an easily digestible manner to be of great value to exploratory or analytical workflows. Furthermore, StarGazer’s other features include the support of initial discoveries by interrogating the precise contribution of evidence from each data source.</p>
  </sec>
  <sec id="s2">
    <title>Data</title>
    <p>Disease-target data are acquired from the PheWAS catalog (<ext-link xlink:href="https://phewascatalog.org/phewas" ext-link-type="uri">https://phewascatalog.org/phewas</ext-link>) and OpenTargets (<ext-link xlink:href="https://genetics.opentargets.org/" ext-link-type="uri">https://genetics.opentargets.org/</ext-link>). The latest PheWAS catalog was created in 2013 by generating odds ratios of association between 3,144 SNPs identified in GWASs and 1,358 phenotypes derived from the electronic medical records of 13,835 individuals of European ancestry, and the data is loaded locally (<xref rid="B17" ref-type="bibr">Denny et al., 2013</xref>). The list of phenotypic variants from the PheWAS catalog as well as from the GWASs within the PheWAS catalog were aggregated and filtered to remove duplicates, producing a list of 1844 phenotypic traits which StarGazer uses for subsequent analysis. OpenTargets version 22.02 is the latest version at the time of writing, and provides 7,980,448 target-disease association scores extracted from 21 public databases containing diverse forms of evidence, from genetic and drug associations to text mining and animal model data amongst others (<xref rid="B41" ref-type="bibr">Ochoa et al., 2021</xref>). Data from OpenTargets is acquired in real-time via API calls.</p>
    <p>Target druggability data are acquired in real-time via API calls through Pharos (<ext-link xlink:href="https://pharos.nih.gov/" ext-link-type="uri">https://pharos.nih.gov/</ext-link>) to access the Target Central Resource Database (TCRD) (<xref rid="B58" ref-type="bibr">Sheils et al., 2021</xref>). The TCRD categorizes 20,412 targets, at the time of writing, into four groups of increasing druggability evidence: Tdark, Tbio, Tchem, and Tclin. A variety of evidence is integrated for classification, such as data from ChEMBL (<xref rid="B38" ref-type="bibr">Mendez et al., 2019</xref>), Guide to Pharmacology (<xref rid="B4" ref-type="bibr">Armstrong et al., 2019</xref>), DrugCentral (<xref rid="B7" ref-type="bibr">Avram et al., 2021</xref>), and antibodypedia (<xref rid="B31" ref-type="bibr">Kiermer, 2008</xref>), amongst many more, as well as gene ontology and text-mining analysis. Tclin genes are already targets of approved drugs, whilst Tchem genes have drugs with evidence of sufficient activity against the gene. Tbio genes have weak evidence for druggability, and Tdark genes have an unknown level of druggability.</p>
    <p>Protein-protein interaction data are acquired in real-time via API calls from the STRING database (<ext-link xlink:href="https://string-db.org/" ext-link-type="uri">https://string-db.org/</ext-link>). STRING version 11.5 contains data of 20,052,394,042 protein-protein interactions from 14,094 organisms, of which only human genes and orthologous genes were used in StarGazer (<xref rid="B61" ref-type="bibr">Szklarczyk et al., 2021</xref>), which were analyzed using the Python package, pyvis. Gene ontology enrichment analysis is also performed by STRING.</p>
  </sec>
  <sec sec-type="methods" id="s3">
    <title>Methods</title>
    <p>StarGazer was built using Streamlit (<ext-link xlink:href="https://streamlit.io/" ext-link-type="uri">https://streamlit.io/</ext-link>), a relatively new Python-based tool for developing web applications for machine learning and data science. It enables data scientists to build web applications purely from Python scripts quickly and seamlessly. The Streamlit dashboard allows for local files to be loaded, as well as data to be requested from databases via real-time API calls. The StarGazer drug target prioritization framework considers the following five features for each disease (<xref rid="F1" ref-type="fig">Figure 1</xref>): (<xref rid="B67" ref-type="bibr">Xue et al., 2018</xref>)—the odds ratios of association between targets and phenotypic variants of interest from GWAS and PheWAS data; (<xref rid="B45" ref-type="bibr">Pushpakom et al., 2019</xref>);—the target-disease association scores from Open Targets; (<xref rid="B35" ref-type="bibr">Li et al., 2016</xref>);—the druggability data of genes of interest from Pharos; (<xref rid="B56" ref-type="bibr">Shameer et al., 2015</xref>);—the degree of nodes in protein-protein interaction networks of genes of interest from STRING; and (<xref rid="B33" ref-type="bibr">Lee and Bhakta, 2021</xref>)—the presence of the gene variant of interest in both PheWAS and GWAS datasets. Each gene was analyzed with respect to each of these five features, and five scores were computed corresponding to each of the above features. These five scores were then normalized to ensure equal maximum contribution, before summing the five normalized scores to obtain an overall score (i.e., the StarGazer score) which has a maximum score of 1. The targets were then ranked in descending order to facilitate target prioritization.</p>
    <fig position="float" id="F1">
      <label>FIGURE 1</label>
      <caption>
        <p>The StarGazer drug target prioritization framework considers the following five features for each of the 1844 diseases in StarGazer’s disease list (<xref rid="B67" ref-type="bibr">Xue et al., 2018</xref>):—the odds ratios of association between targets and phenotypic variants of interest from GWAS and PheWAS data (<xref rid="B45" ref-type="bibr">Pushpakom et al., 2019</xref>);—the target-disease association scores from Open Targets (<xref rid="B35" ref-type="bibr">Li et al., 2016</xref>);—the druggability data of genes of interest from Pharos (<xref rid="B56" ref-type="bibr">Shameer et al., 2015</xref>);—the degree of nodes in protein-protein interaction networks of genes of interest from STRING; and (<xref rid="B33" ref-type="bibr">Lee and Bhakta, 2021</xref>)—the presence of the gene variant of interest in both PheWAS and GWAS datasets. All data, except the PheWAS and GWAS data, are loaded in real-time by API calls and therefore present the latest evidence for drug repositioning strategies. The above five features are then integrated to provide a singular numerical StarGazer score which quantifies the drug repositioning potential of a gene. StarGazer is built on the Python-based Streamlit platform, which is largely used for building sleek and modern web applications for machine-learning and data science.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g001" position="float"/>
    </fig>
    <sec id="s3-1">
      <title>Processing of Disease-Target Data</title>
      <p>Analysis of the PheWAS and GWAS odds ratios involved identifying risk associations where the odds ratio ≥1 (i.e., more associated with the occurrence of the phenotype), and protective associations where the odds ratio &lt;1 (i.e., more associated with the non-occurrence of the disease). In the risk allele-based target prioritization, odds ratios were taken as they were. However, in protective-allele-based target prioritization, odds ratios were subtracted by 1, as the lower ratio implies higher magnitude of association. An average value was taken for odds ratios from multiple studies of the same gene, before normalizing to generate the feature score. Another feature score was generated by determining if the gene target was present in both the PheWAS and GWAS datasets, assigning a score of 1 for the PheWAS-GWAS intersection score, which is otherwise 0. Finally, the target-disease association feature scores from OpenTargets were values between 0 and 1, calculated in a similar manner as the PheWAS catalogue analysis.</p>
    </sec>
    <sec id="s3-2">
      <title>Processing of Target Druggability Data</title>
      <p>For analysis of the druggability data from Pharos, the number of distinct druggability levels that a target has was counted, with the exception of Tdark, e.g., a target with Tbio, Tclin, and Tdark labels is scored 2 (1 + 1 + 0). These scores were then normalized against the highest druggability feature score of each gene.</p>
    </sec>
    <sec id="s3-3">
      <title>Processing of Protein-Protein Interaction Data</title>
      <p>The degree of the node in the protein-protein interaction networks from STRING is the number of proteins directly connected to the target node via functional associations, which include experimentally confirmed interactions, predicted interactions and text mining data. Node degrees were computed for each gene in a network and calculated as a ratio of the highest node degree in that network, as a gene with higher interactivity within a STRING network is more likely to be biologically underpinning the molecular pathway that contributes to a phenotype. The calculation of node degrees scores this way also reduces effects of false positive interactions.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="s4">
    <title>Results</title>
    <p>The StarGazer dashboard (<ext-link xlink:href="https://github.com/AstraZeneca/StarGazer" ext-link-type="uri">https://github.com/AstraZeneca/StarGazer</ext-link>) offers eight modes of data exploration for drug target prioritization using the data analyzed as described in Methods. The modern yet simple interface allows for rapid navigation without the need for specialist training or programming experience. StarGazer allows users to search by genes or gene variants which displays all associated phenotypic variants ranked by odds ratio graphically, as well as in tabular format (<xref rid="F2" ref-type="fig">Figure 2</xref>). Red bars indicate an odds ratio of greater than 1 (i.e., risk association), whilst blue bars indicate less than 1 (i.e., protective association). Users can also search by the PheWAS, GWAS, and GWAS-PheWAS Union modes of exploration, which returns odds ratios of all variants of genes associated with the phenotype of interest from the respective datasets, as well as their corresponding druggability levels (<xref rid="F3" ref-type="fig">Figure 3</xref>). When searching in the GWAS-PheWAS Intersection mode, only variants with associations identified in both GWAS and PheWAS datasets are shown (<xref rid="F4" ref-type="fig">Figure 4</xref>). For these variants, the dashboard also provides association odds ratios, druggability data, protein-protein interaction networks and gene ontology enrichment analysis for the disease of interest (<xref rid="F5" ref-type="fig">Figure 5</xref>). Finally, when users search by disease target prioritization, the overall StarGazer score is shown for each gene with association with the disease of interest (<xref rid="F6" ref-type="fig">Figure 6</xref>). Contextual information on any of these genes can be found immediately using the build-in NCBI search tool. For each of these exploration modes, users can also modify the <italic>p</italic>-value to only display associations of desired statistical significance assigned by the origin data source.</p>
    <fig position="float" id="F2">
      <label>FIGURE 2</label>
      <caption>
        <p>The StarGazer interface after searching “<italic>HLA-G</italic>” in Gene mode. At <italic>p</italic> = 0.05, the first allele returned is rs11206510. The color-coded bar chart shows the odds ratio of association of the allele with each phenotype. The table on the right is the same data tabulated which can be downloaded as a csv file. The StarGazer Variant mode is similar in appearance.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g002" position="float"/>
    </fig>
    <fig position="float" id="F3">
      <label>FIGURE 3</label>
      <caption>
        <p>The StarGazer interface after searching “Multiple sclerosis” in PheWAS mode. At <italic>p</italic> = 0.05, 7.37% of genes with associations with multiple sclerosis were categorized as Tclin, i.e., already targets of FDA-approved drugs. The distribution of genes in each druggability level is shown by pie chart and scatter plot, the latter of which also showing the odds ratios of each allele of each gene. Some gene names are not shown. This data is re-analyzed to show only risk alleles, or only protective alleles. Tabulated data can be visualized and downloaded. The StarGazer modes, GWAS and GWAS-PheWAS Union, are similar in appearance.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g003" position="float"/>
    </fig>
    <fig position="float" id="F4">
      <label>FIGURE 4</label>
      <caption>
        <p>The StarGazer interface after searching “Type 2 diabetes” in GWAS-PheWAS Intersection mode. At <italic>p</italic> = 0.05, 23 SNPs were identified to have associations in both PheWASs and GWASs. Top left: pie chart displaying the proportion of SNPs that were identified in either PheWAS or GWAS datasets, or in both datasets. Top right: pie chart displaying druggability information of the genes of these SNPs. Tclin in red implies genes already have drugs targeting them available on the market, whilst Tchem, Tbio, Tdark, and None, indicate progressively decreasing levels of druggability. Bottom left: scatter plot highlighting individually reported odds-ratios of associations of SNPs from various GWASs. Bottom right: a protein-protein interaction network constructed from the genes of alleles detected in both GWASs and the PheWAS catalog. The gene ontology enrichment analysis feature is not shown in the figure.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g004" position="float"/>
    </fig>
    <fig position="float" id="F5">
      <label>FIGURE 5</label>
      <caption>
        <p>The StarGazer interface after searching “ASCVD” in Protein-protein interaction mode. Protein-protein interaction networks are shown of all alleles, risk alleles, and protective alleles. The node degree of the genes of these alleles are computed, and gene ontology enrichment analysis is performed on the right.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g005" position="float"/>
    </fig>
    <fig position="float" id="F6">
      <label>FIGURE 6</label>
      <caption>
        <p>The StarGazer interface after searching “Breast cancer” in Disease Target Prioritization mode. At <italic>p</italic> = 0.05, 140 genes are returned to have association with breast cancer. Genes are ranked in StarGazer score, which describes how suitable a gene is for drug repositioning. The subsequent five columns are the individual scores of the five features extracted from all of the data that contribute to the StarGazer score. Data are separated into all alleles, risk alleles, then protective alleles, and can be downloaded as csv files.</p>
      </caption>
      <graphic xlink:href="fgene-13-868015-g006" position="float"/>
    </fig>
    <sec id="s4-1">
      <title>Use Case: StarGazer for Understanding Complex Diseases</title>
      <p>In the following case study, we posed as someone who was simply curious about the possible mechanistic causes of insomnia, and consequently adopted a more exploratory workflow. As insomnia is a complex and relatively understudied disorder, we set the <italic>p</italic>-value to a less stringent 0.05 to prevent issues in, for example, study sample size or sensitivity from masking any potentially true associations. This returned a list of 106 genes with associations with insomnia, 62 of which had at least one risk-associated allele, and 46 had at least one protection-associated allele (<xref rid="T1" ref-type="table">Table 1</xref>). After searching on NCBI, there were three genes found to have significant relevance to insomnia. <italic>DISC1</italic> encodes a scaffold protein which is involved in brain development, and its mutations have been implicated in schizophrenia and other psychiatric disorders (<xref rid="B16" ref-type="bibr">Dahoun et al., 2017</xref>); <italic>MAOA</italic> encodes a mitochondrial oxidative deaminase targeting amines such as dopamine, norepinephrine, and serotonin, and mutations in the gene can result in Brunner syndrome, a psychiatric and sleep disorder (<xref rid="B12" ref-type="bibr">Brunner et al., 2007</xref>); <italic>MEIS1</italic> is a HOX gene thought to have a pleiotropic effect on chronic insomnia disorder, and have possible association with restless leg syndrome (<xref rid="B52" ref-type="bibr">Sarayloo et al., 2019</xref>). We also found genes with a variety of functions and unclear links with insomnia. Tumor suppressor genes, <italic>CMTM7</italic> (<xref rid="B34" ref-type="bibr">Li et al., 2014b</xref>), <italic>NKAPL</italic> (<xref rid="B42" ref-type="bibr">Okuda et al., 2015</xref>) and <italic>ATM</italic> (encoding ATM checkpoint kinase) (<xref rid="B59" ref-type="bibr">Shiloh and Ziv, 2013</xref>) may allude to aberrant DNA damage responses contributing to insomnia, and indeed, there are several reports of links between DNA damage and sleep in the literature (<xref rid="B13" ref-type="bibr">Carroll et al., 2016</xref>; <xref rid="B68" ref-type="bibr">Zada et al., 2021</xref>). HLA isoforms indicate a potential immunity-related cause of insomnia (<xref rid="B14" ref-type="bibr">Choo, 2007</xref>). <italic>In vitro</italic> mutants in vesicular trafficking protein, dynamin-1, have impaired ability to recycle neurotransmitter at synapses (<xref rid="B15" ref-type="bibr">Chung et al., 2010</xref>), providing a more obvious potential link with insomnia. Finally, genes with noticeably pleiotropic effect were also found to have a high StarGazer score. One such example is estrogen receptor (<italic>ESR1</italic>), important for gestation in women but is in addition expressed in many non-reproductive tissues in both sexes, as it has roles more broadly in growth and metabolism (<xref rid="B10" ref-type="bibr">Barros and Gustafsson, 2011</xref>). Not only is estrogen receptor linked with breast cancer but also with osteoporosis (<xref rid="B22" ref-type="bibr">Gennari et al., 2007</xref>), and thus makes for a peculiar hit on the StarGazer analysis. Although additional investigations are required to ascertain the link between these genes and phenotypes, it is exciting to hypothesize about the underlying molecular mechanisms. This is especially the case for insomnia, a disorder of sleep which is a biological process we still have a relatively poor understanding of.</p>
      <table-wrap position="float" id="T1">
        <label>TABLE 1</label>
        <caption>
          <p>Top 30 hits from Disease Target Prioritization mode analysis of “Insomnia” using StarGazer.</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead valign="top">
            <tr>
              <th align="left" rowspan="1" colspan="1">Gene Name</th>
              <th align="center" rowspan="1" colspan="1">StarGazer Score</th>
              <th align="center" rowspan="1" colspan="1">Odds-Ratio</th>
              <th align="center" rowspan="1" colspan="1">OpenTargets Associations</th>
              <th align="center" rowspan="1" colspan="1">Indicator Phe/GWAS</th>
              <th align="center" rowspan="1" colspan="1">Druggability Score</th>
              <th align="center" rowspan="1" colspan="1">Network Degree Score</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" rowspan="1" colspan="1">HLA-DRB1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.456</td>
              <td align="char" char="." rowspan="1" colspan="1">0.725</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">1.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.556</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">ESR1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.433</td>
              <td align="char" char="." rowspan="1" colspan="1">0.655</td>
              <td align="char" char="." rowspan="1" colspan="1">0.009</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">1.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">GRIN2B</td>
              <td align="char" char="." rowspan="1" colspan="1">0.407</td>
              <td align="char" char="." rowspan="1" colspan="1">0.756</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.778</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MEIS1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.395</td>
              <td align="char" char="." rowspan="1" colspan="1">0.251</td>
              <td align="char" char="." rowspan="1" colspan="1">1.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MAOA</td>
              <td align="char" char="." rowspan="1" colspan="1">0.344</td>
              <td align="char" char="." rowspan="1" colspan="1">0.888</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.333</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DNM1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.337</td>
              <td align="char" char="." rowspan="1" colspan="1">0.630</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.556</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">HLA-DQB1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.320</td>
              <td align="char" char="." rowspan="1" colspan="1">0.653</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.444</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">BMP4</td>
              <td align="char" char="." rowspan="1" colspan="1">0.307</td>
              <td align="char" char="." rowspan="1" colspan="1">0.591</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.444</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">ATM</td>
              <td align="char" char="." rowspan="1" colspan="1">0.293</td>
              <td align="char" char="." rowspan="1" colspan="1">0.188</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.778</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CMTM7</td>
              <td align="char" char="." rowspan="1" colspan="1">0.288</td>
              <td align="char" char="." rowspan="1" colspan="1">0.941</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">NKAPL</td>
              <td align="char" char="." rowspan="1" colspan="1">0.288</td>
              <td align="char" char="." rowspan="1" colspan="1">0.938</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">GRIA1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.286</td>
              <td align="char" char="." rowspan="1" colspan="1">0.263</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.667</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">TOMM40</td>
              <td align="char" char="." rowspan="1" colspan="1">0.280</td>
              <td align="char" char="." rowspan="1" colspan="1">0.677</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">NR5A2</td>
              <td align="char" char="." rowspan="1" colspan="1">0.278</td>
              <td align="char" char="." rowspan="1" colspan="1">0.668</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">HDAC9</td>
              <td align="char" char="." rowspan="1" colspan="1">0.276</td>
              <td align="char" char="." rowspan="1" colspan="1">0.768</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">MS4A6A</td>
              <td align="char" char="." rowspan="1" colspan="1">0.271</td>
              <td align="char" char="." rowspan="1" colspan="1">0.631</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DISC1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.267</td>
              <td align="char" char="." rowspan="1" colspan="1">0.166</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.667</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">ST6GAL1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.265</td>
              <td align="char" char="." rowspan="1" colspan="1">0.716</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">SLC22A3</td>
              <td align="char" char="." rowspan="1" colspan="1">0.264</td>
              <td align="char" char="." rowspan="1" colspan="1">0.600</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">EFNA5</td>
              <td align="char" char="." rowspan="1" colspan="1">0.264</td>
              <td align="char" char="." rowspan="1" colspan="1">0.600</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">NRGN</td>
              <td align="char" char="." rowspan="1" colspan="1">0.263</td>
              <td align="char" char="." rowspan="1" colspan="1">0.706</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">DRD2</td>
              <td align="char" char="." rowspan="1" colspan="1">0.263</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.150</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.667</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">RNASET2</td>
              <td align="char" char="." rowspan="1" colspan="1">0.263</td>
              <td align="char" char="." rowspan="1" colspan="1">0.591</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.222</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">FGFR2</td>
              <td align="char" char="." rowspan="1" colspan="1">0.263</td>
              <td align="char" char="." rowspan="1" colspan="1">0.257</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.556</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">UBE2L3</td>
              <td align="char" char="." rowspan="1" colspan="1">0.262</td>
              <td align="char" char="." rowspan="1" colspan="1">0.701</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">YDJC</td>
              <td align="char" char="." rowspan="1" colspan="1">0.260</td>
              <td align="char" char="." rowspan="1" colspan="1">0.690</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CDC42BPB</td>
              <td align="char" char="." rowspan="1" colspan="1">0.260</td>
              <td align="char" char="." rowspan="1" colspan="1">0.690</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LAMP3</td>
              <td align="char" char="." rowspan="1" colspan="1">0.258</td>
              <td align="char" char="." rowspan="1" colspan="1">0.791</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">ARG1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.254</td>
              <td align="char" char="." rowspan="1" colspan="1">0.660</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">CCND3</td>
              <td align="char" char="." rowspan="1" colspan="1">0.251</td>
              <td align="char" char="." rowspan="1" colspan="1">0.643</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.000</td>
              <td align="char" char="." rowspan="1" colspan="1">0.500</td>
              <td align="char" char="." rowspan="1" colspan="1">0.111</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s5">
    <title>Discussion</title>
    <p>StarGazer is a novel application built for rapid investigation of drug repositioning strategies. It combines multi-source, multi-omics data with a novel target prioritization scoring system in an interactive Python-based Streamlit dashboard. StarGazer analyzes and integrates disease-target associations, druggability data, and protein-protein interaction data before extracting five features from the data to create an overall StarGazer score for every potential target associated with StarGazer’s curated list of 1844 phenotypic variants.</p>
    <p>StarGazer is adapted to facilitate exploration of the human biology landscape from a birds-eye view, allowing rapid digestion of information from PheWASs/GWASs, which otherwise contains many tens of thousands of complex multivariate datapoints. Streamlit, as a user interface package adapted for complex data visualization and user interactivity, was considered to be a well-suited technology for such a task. Indeed, the importance of the flexibility in visualization methods, and live data retrieval and analysis is becoming increasingly clear, with their applications ever-expanding (<xref rid="B8" ref-type="bibr">Badgeley et al., 2016</xref>; <xref rid="B39" ref-type="bibr">Moosavinasab et al., 2016</xref>).</p>
    <p>We demonstrate the utility in integrating several omics datasets and returning easy-to-interpret analysis metrics in an interactive dashboard. One can easily imagine the power of such a strategy as we incorporate state-of-the-art, machine learning-based, multi-omics integration techniques, as well as a wider variety of high quality data. In an era where the speed at which we can generate data is accelerating at a higher rate than we can analyze it, we anticipate that integrative scores and visualization tools will grow increasingly essential in biology, and that we must begin to break away from the more rigid, single-use analysis framework that forms the modern paradigm for analyzing not just GWAS and PheWAS data (<xref rid="B19" ref-type="bibr">Diogo et al., 2018</xref>; <xref rid="B20" ref-type="bibr">Ferrero and Agarwal, 2018</xref>; <xref rid="B50" ref-type="bibr">Robinson et al., 2018</xref>; <xref rid="B32" ref-type="bibr">Lau and So, 2020</xref>), but multi-omics data in general (<xref rid="B60" ref-type="bibr">Subramanian et al., 2020</xref>).</p>
    <p>StarGazer has been built with the goal of pushing multi-omics integration towards upward scalability by providing users with immediate access to contextual information on genes of potential interest by automatically performing several steps of follow-up analysis on all genes - this saves a considerable amount of time from performing speculative follow-up analysis. These follow-up analysis steps are completed in bulk through the processing of the single-omic layers, which removes the need for users to analyze every gene separately for various properties and then later compare the results to make sense of the evidence. Not only does integrating single-omic layers increase the speed of exploratory data analysis, but it also provides additional value from combining multiple pieces of evidence as opposed to focusing on individual single high-confidence pieces of information, especially when the different types of data are likely to have an intimate biological relationship, e.g., combining a gene’s DNA, RNA and protein information together is likely to be more valuable than analyzing them independently as they are functionally coupled. This approach may be our best strategy for uncovering complex and profound relationships and hence, the phrase “the whole is greater than the sum of its parts” holds particularly true in the context of multi-omics data analysis. A more integrated strategy may also be more useful in helping us understand the genetic basis of complex diseases driven by genes and gene variants with pleiotropic functions or effects. Applying the latest ideas on pleiotropy in biological systems to future work may allow us to obtain a more complete understanding of genome-phenome relationships and thus drive novel discoveries previously inaccessible in the biomedical field (<xref rid="B53" ref-type="bibr">Shameer et al., 2021</xref>).</p>
    <sec id="s5-1">
      <title>Limitations</title>
      <p>This should, of course, highlight to the reader the current co-dependence between broader exploratory analytical approaches, such as StarGazer, with those that possess stronger statistical power, aimed at target confirmation at the cost of breadth and fewer omics layers, and of course, experimental confirmation. Moving forwards, we should hope that the field develops more sophisticated strategies for these types of analysis. All in all, we anticipate StarGazer to be potentially useful in providing insights into many types of biological pathways, as long as the molecular perturbations that are linked with disease lie close to the genetic level. Whilst it is easy to imagine StarGazer’s utility for studying diseases caused by variants of proteins or nucleic acids due to their more direct connection to genome-level information, studying metabolic disorders of carbohydrates and lipids would be possible but more difficult.</p>
      <p>We wish to highlight that, although the barrier to entry for multi-omics data analysis is low, there seems yet a limitless space for improvement in the field at the time of writing. In the future, we aim to incorporate gene ontology terms enrichment analysis, gene semantic similarity, and gene expression data into our target prioritization framework, and improve on the implementation of protein-protein interaction networks (<xref rid="B57" ref-type="bibr">Shameer et al., 2016</xref>; <xref rid="B43" ref-type="bibr">Peters et al., 2017</xref>). Whilst the current version of StarGazer extracts several features for target-disease associations, the assessment of target druggability uses only one dataset to generate one feature. Although the knowledge-based classification of the genome that Pharos provides is very high quality data, it is less indicative of future potential developments as it reflects only the current status of the druggability landscape of human biology. Therefore, more predictive datasets, such as computational docking predictions using structural data from molecular techniques or even AI-based computational prediction, may provide more robust insight into the future (<xref rid="B9" ref-type="bibr">Baek et al., 2021</xref>; <xref rid="B28" ref-type="bibr">Jumper et al., 2021</xref>).</p>
      <p>StarGazer’s use of API calls allows for the majority of its data to be updated automatically with the latest relevant studies, aside from the PheWAS catalog which was performed in 2013—it would be invaluable if a similar study was repeated to include the GWAS data which was generated during the decade that has elapsed since the original effort. Furthermore, a variety of machine learning strategies have been applied to multi-omics data analysis and show great promise in assisting precision medicine and repositioning (<xref rid="B55" ref-type="bibr">Shameer et al., 2018b</xref>; <xref rid="B40" ref-type="bibr">Nicora et al., 2020</xref>; <xref rid="B49" ref-type="bibr">Reel et al., 2021</xref>), and is therefore an area we are interested in developing for StarGazer. Another avenue for future development is to improve on the standardization of clinical terms between the different datasets, which is a problem not unique to StarGazer but found ubiquitously in healthcare-related work (<xref rid="B64" ref-type="bibr">Wears, 2015</xref>; <xref rid="B11" ref-type="bibr">Beck et al., 2019</xref>). This problem manifested itself as data from OpenTargets being underrepresented in the overall StarGazer score. We hypothesize that using a combination of standardized codes for clinical terms, such as ICD-9/-10 (<ext-link xlink:href="https://www.cdc.gov/nchs/icd/icd9.htm" ext-link-type="uri">https://www.cdc.gov/nchs/icd/icd9.htm</ext-link>, <ext-link xlink:href="https://www.cdc.gov/nchs/icd/icd10.htm" ext-link-type="uri">https://www.cdc.gov/nchs/icd/icd10.htm</ext-link>), and EFO (<ext-link xlink:href="https://www.ebi.ac.uk/efo/faq.html" ext-link-type="uri">https://www.ebi.ac.uk/efo/faq.html</ext-link>), would help with this problem, as well as further curate our list of 1844 phenotypic variants. Currently, the code for installation can be found on GitHub (<ext-link xlink:href="https://github.com/AstraZeneca/StarGazer" ext-link-type="uri">https://github.com/AstraZeneca/StarGazer</ext-link>).</p>
    </sec>
  </sec>
  <sec sec-type="conclusion" id="s6">
    <title>Conclusion</title>
    <p>We have created StarGazer (<ext-link xlink:href="https://github.com/AstraZeneca/StarGazer" ext-link-type="uri">https://github.com/AstraZeneca/StarGazer</ext-link>), an interactive dashboard that facilitates rapid investigation of potential novel drug targets and repositioning strategies. It integrates three different types of data (disease-target data, target druggability data, and protein-protein interaction data) from four different knowledgebases (the PheWAS catalog, OpenTargets, Pharos, and STRING) to extract five features that are then processed to return a singular normalized “StarGazer” score. All genes with associations with any of the 1844 phenotypic variants in the StarGazer disease list are then ranked in suitability for drug repositioning strategies for the disease of interest.</p>
    <p>We demonstrate the utility in integrating several omics datasets to return easy-to-interpret analysis metrics in an interactive dashboard. One can easily imagine the power of such a strategy as we incorporate machine learning techniques as well as a wider variety of high quality data. It is anticipated that such integrative analysis strategies will become commonplace as biomedical data science grows to explore more multi-disciplinary and multi-omic datasets. Integrative scores and visualization tools for high dimensional data will become essential as we navigate science in this era where we are generating data at a such an enormous pace, thus we have positioned StarGazer to push multi-omics integration towards upward scalability.</p>
  </sec>
</body>
<back>
  <ack>
    <p>The authors would like to acknowledge Anshul Kanakia for insightful discussions, and Stefano Borini for assistance with GitHub.</p>
  </ack>
  <sec sec-type="data-availability" id="s7">
    <title>Data Availability Statement</title>
    <p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: <ext-link xlink:href="https://github.com/AstraZeneca/StarGazer" ext-link-type="uri">https://github.com/AstraZeneca/StarGazer</ext-link>.</p>
  </sec>
  <sec id="s8">
    <title>Author Contributions</title>
    <p>CL and JL developed the project with critical inputs from VG, AF, MH, KT, BS, TC, JM, and YG. MH led app hosting, and AP and RNH conducted validation analysis. KS led and oversaw the project. The original manuscript was written by CL and JL, with additions and edits provided by VG, EP, AF, SP, WY, A-SS, KT, BS, TC, JM, FMK, YG, and KS. All authors contributed to the article and approved the submitted version.</p>
  </sec>
  <sec sec-type="COI-statement" id="s9">
    <title>Conflict of Interest</title>
    <p>Authors CL, AP, VG, RNH, EP, AF, SP, WY, MH, A-SS, KT, BS, TC, JM, FMK, and KS are or were employed by AstraZeneca.</p>
    <p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
  </sec>
  <sec sec-type="disclaimer" id="s10">
    <title>Publisher’s Note</title>
    <p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Doleh</surname><given-names>A. A.</given-names></name><name><surname>Al-Jarrah</surname><given-names>O. M.</given-names></name><name><surname>Alkhateeb</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Protein Contact Map Prediction Using Multi-Stage Hybrid Intelligence Inference Systems</article-title>. <source>J. Biomed. Inf.</source>
<volume>45</volume> (<issue>1</issue>), <fpage>173</fpage>–<lpage>183</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbi.2011.10.008</pub-id>
</mixed-citation>
    </ref>
    <ref id="B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adikusuma</surname><given-names>W.</given-names></name><name><surname>Irham</surname><given-names>L. M.</given-names></name><name><surname>Chou</surname><given-names>W.-H.</given-names></name><name><surname>Wong</surname><given-names>H. S.-C.</given-names></name><name><surname>Mugiyanto</surname><given-names>E.</given-names></name><name><surname>Ting</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information</article-title>. <source>Front. Immunol.</source>
<volume>12</volume>, <fpage>724277</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.724277</pub-id>
<pub-id pub-id-type="pmid">34721386</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akata</surname><given-names>Z.</given-names></name><name><surname>Eiben</surname><given-names>G.</given-names></name><name><surname>Fokkens</surname><given-names>A.</given-names></name><name><surname>Grossi</surname><given-names>D.</given-names></name><name><surname>Hindriks</surname><given-names>K.</given-names></name><name><surname>Hoos</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>A Research Agenda for Hybrid Intelligence: Augmenting Human Intellect with Collaborative, Adaptive, Responsible, and Explainable Artificial Intelligence</article-title>. <source>Computer</source>
<volume>53</volume>, <fpage>18</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1109/mc.2020.2996587</pub-id>
</mixed-citation>
    </ref>
    <ref id="B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>J. F.</given-names></name><name><surname>Faccenda</surname><given-names>E.</given-names></name><name><surname>Harding</surname><given-names>S. D.</given-names></name><name><surname>Pawson</surname><given-names>A. J.</given-names></name><name><surname>Southan</surname><given-names>C.</given-names></name><name><surname>Sharman</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: Extending Immunopharmacology Content and Introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY</article-title>. <source>Nucleic Acids Res.</source>
<volume>48</volume>, <fpage>D1006</fpage>–<lpage>D1021</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz951</pub-id>
</mixed-citation>
    </ref>
    <ref id="B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburn</surname><given-names>T. T.</given-names></name><name><surname>Thor</surname><given-names>K. B.</given-names></name></person-group> (<year>2004</year>). <article-title>Drug Repositioning: Identifying and Developing New Uses for Existing Drugs</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>3</volume> (<issue>8</issue>), <fpage>673</fpage>–<lpage>683</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1468</pub-id>
<pub-id pub-id-type="pmid">15286734</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attique</surname><given-names>Z.</given-names></name><name><surname>Ali</surname><given-names>A.</given-names></name><name><surname>Hamza</surname><given-names>M.</given-names></name><name><surname>al-Ghanim</surname><given-names>K. A.</given-names></name><name><surname>Mehmood</surname><given-names>A.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>In-silico Network-Based Analysis of Drugs Used against COVID-19: Human Well-Being Study</article-title>. <source>Saudi J. Biol. Sci.</source>
<volume>28</volume> (<issue>3</issue>), <fpage>2029</fpage>–<lpage>2039</lpage>. <pub-id pub-id-type="doi">10.1016/j.sjbs.2021.01.006</pub-id>
<pub-id pub-id-type="pmid">33519272</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avram</surname><given-names>S.</given-names></name><name><surname>Bologa</surname><given-names>C. G.</given-names></name><name><surname>Holmes</surname><given-names>J.</given-names></name><name><surname>Bocci</surname><given-names>G.</given-names></name><name><surname>Wilson</surname><given-names>T. B.</given-names></name><name><surname>Nguyen</surname><given-names>D.-T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>DrugCentral 2021 Supports Drug Discovery and Repositioning</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D1160</fpage>–<lpage>D1169</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa997</pub-id>
<pub-id pub-id-type="pmid">33151287</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badgeley</surname><given-names>M. A.</given-names></name><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Glicksberg</surname><given-names>B. S.</given-names></name><name><surname>Tomlinson</surname><given-names>M. S.</given-names></name><name><surname>Levin</surname><given-names>M. A.</given-names></name><name><surname>McCormick</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>EHDViz: Clinical Dashboard Development Using Open-Source Technologies</article-title>. <source>BMJ Open</source>
<volume>6</volume> (<issue>3</issue>), <fpage>e010579</fpage>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-010579</pub-id>
</mixed-citation>
    </ref>
    <ref id="B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>M.</given-names></name><name><surname>DiMaio</surname><given-names>F.</given-names></name><name><surname>Anishchenko</surname><given-names>I.</given-names></name><name><surname>Dauparas</surname><given-names>J.</given-names></name><name><surname>Ovchinnikov</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>G. R.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Accurate Prediction of Protein Structures and Interactions Using a Three-Track Neural Network</article-title>. <source>Science</source>
<volume>373</volume> (<issue>6557</issue>), <fpage>871</fpage>–<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1126/science.abj8754</pub-id>
<pub-id pub-id-type="pmid">34282049</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barros</surname><given-names>R. P. A.</given-names></name><name><surname>Gustafsson</surname><given-names>J.-Å.</given-names></name></person-group> (<year>2011</year>). <article-title>Estrogen Receptors and the Metabolic Network</article-title>. <source>Cell Metab.</source>
<volume>14</volume> (<issue>3</issue>), <fpage>289</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2011.08.005</pub-id>
<pub-id pub-id-type="pmid">21907136</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>T.</given-names></name><name><surname>Shorter</surname><given-names>T.</given-names></name><name><surname>Brookes</surname><given-names>A. J.</given-names></name></person-group> (<year>2019</year>). <article-title>GWAS Central: a Comprehensive Resource for the Discovery and Comparison of Genotype and Phenotype Data from Genome-wide Association Studies</article-title>. <source>Nucleic Acids Res.</source>
<volume>48</volume>, <fpage>D933</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkz895</pub-id>
</mixed-citation>
    </ref>
    <ref id="B12">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>H. G.</given-names></name></person-group> (<year>2007</year>). “<article-title>MAOA Deficiency and Abnormal Behaviour: Perspectives on an Assocation</article-title>,” in <source>Novartis Foundation Symposia [Internet]</source>. Editors <person-group person-group-type="editor"><name><surname>Bock</surname><given-names>G. R.</given-names></name><name><surname>Goode</surname><given-names>J. A.</given-names></name></person-group> (<publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley &amp; Sons</publisher-name>), <fpage>155</fpage>–<lpage>167</lpage>. <comment>Available at: <ext-link xlink:href="https://onlinelibrary.wiley.com/doi/10.1002/9780470514825.ch9" ext-link-type="uri">https://onlinelibrary.wiley.com/doi/10.1002/9780470514825.ch9</ext-link>
</comment>. <pub-id pub-id-type="doi">10.1002/9780470514825.ch9</pub-id>
</mixed-citation>
    </ref>
    <ref id="B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>J. E.</given-names></name><name><surname>Cole</surname><given-names>S. W.</given-names></name><name><surname>Seeman</surname><given-names>T. E.</given-names></name><name><surname>Breen</surname><given-names>E. C.</given-names></name><name><surname>Witarama</surname><given-names>T.</given-names></name><name><surname>Arevalo</surname><given-names>J. M. G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Partial Sleep Deprivation Activates the DNA Damage Response (DDR) and the Senescence-Associated Secretory Phenotype (SASP) in Aged Adult Humans</article-title>. <source>Brain, Behav. Immun.</source>
<volume>51</volume>, <fpage>223</fpage>–<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.08.024</pub-id>
<pub-id pub-id-type="pmid">26336034</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>S. Y.</given-names></name></person-group> (<year>2007</year>). <article-title>The HLA System: Genetics, Immunology, Clinical Testing, and Clinical Implications</article-title>. <source>Yonsei Med. J.</source>
<volume>48</volume> (<issue>1</issue>), <fpage>11</fpage>. <pub-id pub-id-type="doi">10.3349/ymj.2007.48.1.11</pub-id>
<pub-id pub-id-type="pmid">17326240</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>C.</given-names></name><name><surname>Barylko</surname><given-names>B.</given-names></name><name><surname>Leitz</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Kavalali</surname><given-names>E. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Acute Dynamin Inhibition Dissects Synaptic Vesicle Recycling Pathways that Drive Spontaneous and Evoked Neurotransmission</article-title>. <source>J. Neurosci.</source>
<volume>30</volume> (<issue>4</issue>), <fpage>1363</fpage>–<lpage>1376</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.3427-09.2010</pub-id>
<pub-id pub-id-type="pmid">20107062</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahoun</surname><given-names>T.</given-names></name><name><surname>Trossbach</surname><given-names>S. V.</given-names></name><name><surname>Brandon</surname><given-names>N. J.</given-names></name><name><surname>Korth</surname><given-names>C.</given-names></name><name><surname>Howes</surname><given-names>O. D.</given-names></name></person-group> (<year>2017</year>). <article-title>The Impact of Disrupted-In-Schizophrenia 1 (DISC1) on the Dopaminergic System: a Systematic Review</article-title>. <source>Transl. Psychiatry</source>
<volume>7</volume> (<issue>1</issue>), <fpage>e1015</fpage>. <pub-id pub-id-type="doi">10.1510.1038/tp.2016.282</pub-id>
<pub-id pub-id-type="pmid">28140405</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>J. C.</given-names></name><name><surname>Bastarache</surname><given-names>L.</given-names></name><name><surname>Ritchie</surname><given-names>M. D.</given-names></name><name><surname>Carroll</surname><given-names>R. J.</given-names></name><name><surname>Zink</surname><given-names>R.</given-names></name><name><surname>Mosley</surname><given-names>J. D.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Systematic Comparison of Phenome-wide Association Study of Electronic Medical Record Data and Genome-wide Association Study Data</article-title>. <source>Nat. Biotechnol.</source>
<volume>31</volume> (<issue>12</issue>), <fpage>1102</fpage>–<lpage>1111</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2749</pub-id>
<pub-id pub-id-type="pmid">24270849</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denny</surname><given-names>J. C.</given-names></name><name><surname>Ritchie</surname><given-names>M. D.</given-names></name><name><surname>Basford</surname><given-names>M. A.</given-names></name><name><surname>Pulley</surname><given-names>J. M.</given-names></name><name><surname>Bastarache</surname><given-names>L.</given-names></name><name><surname>Brown-Gentry</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>PheWAS: Demonstrating the Feasibility of a Phenome-wide Scan to Discover Gene-Disease Associations</article-title>. <source>Bioinformatics</source>
<volume>26</volume> (<issue>9</issue>), <fpage>1205</fpage>–<lpage>1210</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btq126</pub-id>
<pub-id pub-id-type="pmid">20335276</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diogo</surname><given-names>D.</given-names></name><name><surname>Tian</surname><given-names>C.</given-names></name><name><surname>Franklin</surname><given-names>C. S.</given-names></name><name><surname>Alanne-Kinnunen</surname><given-names>M.</given-names></name><name><surname>March</surname><given-names>M.</given-names></name><name><surname>Spencer</surname><given-names>C. C. A.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Phenome-wide Association Studies across Large Population Cohorts Support Drug Target Validation</article-title>. <source>Nat. Commun.</source>
<volume>9</volume> (<issue>1</issue>), <fpage>4285</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-018-06540-3</pub-id>
<pub-id pub-id-type="pmid">30327483</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrero</surname><given-names>E.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Connecting Genetics and Gene Expression Data for Target Prioritisation and Drug Repositioning</article-title>. <source>BioData Min.</source>
<volume>11</volume> (<issue>1</issue>), <fpage>7</fpage>. <pub-id pub-id-type="doi">10.1186/s13040-018-0171-y</pub-id>
<pub-id pub-id-type="pmid">29881461</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>K.</given-names></name><name><surname>Goede</surname><given-names>A.</given-names></name><name><surname>Eckert</surname><given-names>A.</given-names></name><name><surname>Moahamed</surname><given-names>B.</given-names></name><name><surname>Preissner</surname><given-names>R.</given-names></name><name><surname>Gohlke</surname><given-names>B.-O.</given-names></name></person-group> (<year>2021</year>). <article-title>PROMISCUOUS 2.0: a Resource for Drug-Repositioning</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D1373</fpage>–<lpage>D1380</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1061</pub-id>
<pub-id pub-id-type="pmid">33196798</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>L.</given-names></name><name><surname>Merlotti</surname><given-names>D.</given-names></name><name><surname>Valleggi</surname><given-names>F.</given-names></name><name><surname>Martini</surname><given-names>G.</given-names></name><name><surname>Nuti</surname><given-names>R.</given-names></name></person-group> (<year>2007</year>). <article-title>Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis</article-title>. <source>Drugs &amp; Aging</source>
<volume>24</volume> (<issue>5</issue>), <fpage>361</fpage>–<lpage>379</lpage>. <pub-id pub-id-type="doi">10.2165/00002512-200724050-00002</pub-id>
<pub-id pub-id-type="pmid">17503894</pub-id></mixed-citation>
    </ref>
    <ref id="B23">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghoussaini</surname><given-names>M.</given-names></name><name><surname>Mountjoy</surname><given-names>E.</given-names></name><name><surname>Carmona</surname><given-names>M.</given-names></name><name><surname>Peat</surname><given-names>G.</given-names></name><name><surname>Schmidt</surname><given-names>E. M.</given-names></name><name><surname>Hercules</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Open Targets Genetics: Systematic Identification of Trait-Associated Genes Using Large-Scale Genetics and Functional Genomics</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D1311</fpage>–<lpage>D1320</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa840</pub-id>
<pub-id pub-id-type="pmid">33045747</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Glicksberg</surname><given-names>B. S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Cheng</surname><given-names>W-Y.</given-names></name><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Hakenberg</surname><given-names>J.</given-names></name><name><surname>Castellanos</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014</year>). “<article-title>An Integrative Pipeline for Multi-Modal Discovery of Disease Relationships</article-title>,” in <source>Biocomputing 2015 [Internet]</source> (<publisher-loc>Hawaii, USA</publisher-loc>: <publisher-name>World Scientific</publisher-name>), <fpage>407</fpage>–<lpage>418</lpage>. <comment>Available from: <ext-link xlink:href="http://www.worldscientific.com/doi/abs/10.1142/9789814644730_0039" ext-link-type="uri">http://www.worldscientific.com/doi/abs/10.1142/9789814644730_0039</ext-link>.</comment>
</mixed-citation>
    </ref>
    <ref id="B25">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Wan</surname><given-names>S.</given-names></name><name><surname>Shang</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Hybrid Intelligence-Driven Medical Image Recognition for Remote Patient Diagnosis in Internet of Medical Things</article-title>. <source>IEEE J. Biomed. Health Inf.</source>
<pub-id pub-id-type="doi">10.1109/jbhi.2021.3139541</pub-id>
</mixed-citation>
    </ref>
    <ref id="B26">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermawan</surname><given-names>A.</given-names></name><name><surname>Putri</surname><given-names>H.</given-names></name><name><surname>Utomo</surname><given-names>R. Y.</given-names></name></person-group> (<year>2020</year>). <article-title>Functional Network Analysis Reveals Potential Repurposing of β-blocker Atenolol for Pancreatic Cancer Therapy</article-title>. <source>DARU J. Pharm. Sci.</source>
<volume>28</volume> (<issue>2</issue>), <fpage>685</fpage>–<lpage>699</lpage>. <pub-id pub-id-type="doi">10.1007/s40199-020-00375-4</pub-id>
</mixed-citation>
    </ref>
    <ref id="B27">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodos</surname><given-names>R. A.</given-names></name><name><surname>Kidd</surname><given-names>B. A.</given-names></name><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Readhead</surname><given-names>B. P.</given-names></name><name><surname>Dudley</surname><given-names>J. T.</given-names></name></person-group> (<year>2016</year>). <article-title>In Silico methods for Drug Repurposing and Pharmacology</article-title>. <source>WIREs Mech. Dis.</source>
<volume>8</volume> (<issue>3</issue>), <fpage>186</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1002/wsbm.1337</pub-id>
</mixed-citation>
    </ref>
    <ref id="B28">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name><name><surname>Pritzel</surname><given-names>A.</given-names></name><name><surname>Green</surname><given-names>T.</given-names></name><name><surname>Figurnov</surname><given-names>M.</given-names></name><name><surname>Ronneberger</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Highly Accurate Protein Structure Prediction with AlphaFold</article-title>. <source>Nature</source>
<volume>596</volume> (<issue>7873</issue>), <fpage>583</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id>
<pub-id pub-id-type="pmid">34265844</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaladkar</surname><given-names>M.</given-names></name><name><surname>Koscielny</surname><given-names>G.</given-names></name><name><surname>Hasan</surname><given-names>S.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name><name><surname>Dunham</surname><given-names>I.</given-names></name><name><surname>Rajpal</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Uncovering Novel Repositioning Opportunities Using the Open Targets Platform</article-title>. <source>Drug Discov. Today</source>
<volume>22</volume> (<issue>12</issue>), <fpage>1800</fpage>–<lpage>1807</lpage>. <pub-id pub-id-type="doi">10.1016/j.drudis.2017.09.007</pub-id>
<pub-id pub-id-type="pmid">28919242</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosravi</surname><given-names>A.</given-names></name><name><surname>Jayaram</surname><given-names>B.</given-names></name><name><surname>Goliaei</surname><given-names>B.</given-names></name><name><surname>Masoudi-Nejad</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>Active Repurposing of Drug Candidates for Melanoma Based on GWAS, PheWAS and a Wide Range of Omics Data</article-title>. <source>Mol. Med.</source>
<volume>25</volume> (<issue>1</issue>), <fpage>30</fpage>. <pub-id pub-id-type="doi">10.1186/s10020-019-0098-x</pub-id>
<pub-id pub-id-type="pmid">31221082</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiermer</surname><given-names>V.</given-names></name></person-group> (<year>2008</year>). <article-title>Antibodypedia</article-title>. <source>Nat. Methods</source>
<volume>5</volume> (<issue>10</issue>), <fpage>860</fpage>. <pub-id pub-id-type="doi">10.1038/nmeth1008-860</pub-id>
</mixed-citation>
    </ref>
    <ref id="B32">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>A.</given-names></name><name><surname>So</surname><given-names>H.-C.</given-names></name></person-group> (<year>2020</year>). <article-title>Turning Genome-wide Association Study Findings into Opportunities for Drug Repositioning</article-title>. <source>Comput. Struct. Biotechnol. J.</source>
<volume>18</volume>, <fpage>1639</fpage>–<lpage>1650</lpage>. <pub-id pub-id-type="doi">10.1016/j.csbj.2020.06.015</pub-id>
<pub-id pub-id-type="pmid">32670504</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Bhakta</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review</article-title>. <source>Antibiotics</source>
<volume>10</volume> (<issue>1</issue>), <fpage>91</fpage>. <pub-id pub-id-type="doi">10.3390/antibiotics10010091</pub-id>
<pub-id pub-id-type="pmid">33477812</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>A Novel 3p22.3 Gene CMTM7 Represses Oncogenic EGFR Signaling and Inhibits Cancer Cell Growth</article-title>. <source>Oncogene</source>
<volume>33</volume> (<issue>24</issue>), <fpage>3109</fpage>–<lpage>3118</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.282</pub-id>
<pub-id pub-id-type="pmid">23893243</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Butte</surname><given-names>A. J.</given-names></name><name><surname>Swamidass</surname><given-names>S. J.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name></person-group> (<year>2016</year>). <article-title>A Survey of Current Trends in Computational Drug Repositioning</article-title>. <source>Brief. Bioinform</source>
<volume>17</volume> (<issue>1</issue>), <fpage>2</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbv020</pub-id>
<pub-id pub-id-type="pmid">25832646</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Kang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>X. M.</given-names></name></person-group> (<year>2014</year>). <article-title>A Survey on Evolutionary Algorithm Based Hybrid Intelligence in Bioinformatics</article-title>. <source>Biomed. Res. Int.</source>
<volume>2014</volume>, <fpage>362738</fpage>. <pub-id pub-id-type="doi">10.1155/2014/362738</pub-id>
<pub-id pub-id-type="pmid">24729969</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Borlak</surname><given-names>J.</given-names></name><name><surname>Tong</surname><given-names>W.</given-names></name></person-group> (<year>2014</year>). <article-title>Deciphering miRNA Transcription Factor Feed-Forward Loops to Identify Drug Repurposing Candidates for Cystic Fibrosis</article-title>. <source>Genome Med.</source>
<volume>6</volume> (<issue>12</issue>), <fpage>94</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-014-0094-2</pub-id>
<pub-id pub-id-type="pmid">25484921</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>D.</given-names></name><name><surname>Gaulton</surname><given-names>A.</given-names></name><name><surname>Bento</surname><given-names>A. P.</given-names></name><name><surname>Chambers</surname><given-names>J.</given-names></name><name><surname>De Veij</surname><given-names>M.</given-names></name><name><surname>Félix</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>ChEMBL: towards Direct Deposition of Bioassay Data</article-title>. <source>Nucleic Acids Res.</source>
<volume>47</volume> (<issue>D1</issue>), <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>
<pub-id pub-id-type="pmid">30398643</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moosavinasab</surname><given-names>S.</given-names></name><name><surname>Patterson</surname><given-names>J.</given-names></name><name><surname>Strouse</surname><given-names>R.</given-names></name><name><surname>Rastegar-Mojarad</surname><given-names>M.</given-names></name><name><surname>Regan</surname><given-names>K.</given-names></name><name><surname>Payne</surname><given-names>P. R. O.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>'RE:fine Drugs': an Interactive Dashboard to Access Drug Repurposing Opportunities</article-title>. <source>Database</source>
<volume>2016</volume>, <fpage>baw083</fpage>. <pub-id pub-id-type="doi">10.1093/database/baw083</pub-id>
<pub-id pub-id-type="pmid">27189611</pub-id></mixed-citation>
    </ref>
    <ref id="B40">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicora</surname><given-names>G.</given-names></name><name><surname>Vitali</surname><given-names>F.</given-names></name><name><surname>Dagliati</surname><given-names>A.</given-names></name><name><surname>Geifman</surname><given-names>N.</given-names></name><name><surname>Bellazzi</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Integrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools</article-title>. <source>Front. Oncol.</source>
<volume>10</volume>, <fpage>1030</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2020.01030</pub-id>
<pub-id pub-id-type="pmid">32695678</pub-id></mixed-citation>
    </ref>
    <ref id="B41">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa</surname><given-names>D.</given-names></name><name><surname>Hercules</surname><given-names>A.</given-names></name><name><surname>Carmona</surname><given-names>M.</given-names></name><name><surname>Suveges</surname><given-names>D.</given-names></name><name><surname>Gonzalez-Uriarte</surname><given-names>A.</given-names></name><name><surname>Malangone</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Open Targets Platform: Supporting Systematic Drug-Target Identification and Prioritisation</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D1302</fpage>–<lpage>D1310</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1027</pub-id>
<pub-id pub-id-type="pmid">33196847</pub-id></mixed-citation>
    </ref>
    <ref id="B42">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>H.</given-names></name><name><surname>Kiuchi</surname><given-names>H.</given-names></name><name><surname>Takao</surname><given-names>T.</given-names></name><name><surname>Miyagawa</surname><given-names>Y.</given-names></name><name><surname>Tsujimura</surname><given-names>A.</given-names></name><name><surname>Nonomura</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A Novel Transcriptional Factor Nkapl Is a Germ Cell-specific Suppressor of Notch Signaling and Is Indispensable for Spermatogenesis</article-title>. <source>PLOS ONE</source>
<volume>10</volume> (<issue>4</issue>), <fpage>e0124293</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0124293</pub-id>
<pub-id pub-id-type="pmid">25875095</pub-id></mixed-citation>
    </ref>
    <ref id="B43">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>L. A.</given-names></name><name><surname>Perrigoue</surname><given-names>J.</given-names></name><name><surname>Mortha</surname><given-names>A.</given-names></name><name><surname>Iuga</surname><given-names>A.</given-names></name><name><surname>Song</surname><given-names>W.-m.</given-names></name><name><surname>Neiman</surname><given-names>E. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A Functional Genomics Predictive Network Model Identifies Regulators of Inflammatory Bowel Disease</article-title>. <source>Nat. Genet.</source>
<volume>49</volume> (<issue>10</issue>), <fpage>1437</fpage>–<lpage>1449</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3947</pub-id>
<pub-id pub-id-type="pmid">28892060</pub-id></mixed-citation>
    </ref>
    <ref id="B44">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelli</surname><given-names>M. A.</given-names></name><name><surname>Rakkar</surname><given-names>K.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Adcock</surname><given-names>I. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Translational Analysis of Moderate to Severe Asthma GWAS Signals into Candidate Causal Genes and Their Functional, Tissue-dependent and Disease-Related Associations</article-title>. <source>Front. Allergy</source>
<volume>2</volume>, <fpage>738741</fpage>. <pub-id pub-id-type="doi">10.3389/falgy.2021.738741</pub-id>
<pub-id pub-id-type="pmid">35386986</pub-id></mixed-citation>
    </ref>
    <ref id="B45">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pushpakom</surname><given-names>S.</given-names></name><name><surname>Iorio</surname><given-names>F.</given-names></name><name><surname>Eyers</surname><given-names>P. A.</given-names></name><name><surname>Escott</surname><given-names>K. J.</given-names></name><name><surname>Hopper</surname><given-names>S.</given-names></name><name><surname>Wells</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Drug Repurposing: Progress, Challenges and Recommendations</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>18</volume> (<issue>1</issue>), <fpage>41</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2018.168</pub-id>
<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation>
    </ref>
    <ref id="B46">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rapicavoli</surname><given-names>R. V.</given-names></name><name><surname>Alaimo</surname><given-names>S.</given-names></name><name><surname>Ferro</surname><given-names>A.</given-names></name><name><surname>Pulvirenti</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). “<article-title>Computational Methods for Drug Repurposing</article-title>,” in <source>Computational Methods for Precision Oncology [Internet]</source>. Editor <person-group person-group-type="editor"><name><surname>Laganà</surname><given-names>A.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>119</fpage>–<lpage>141</lpage>. <comment>Available at: <ext-link xlink:href="https://link.springer.com/10.1007/978-3-030-91836-1_7" ext-link-type="uri">https://link.springer.com/10.1007/978-3-030-91836-1_7</ext-link>
</comment>. <pub-id pub-id-type="doi">10.1007/978-3-030-91836-1_7</pub-id>
</mixed-citation>
    </ref>
    <ref id="B47">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastegar-Mojarad</surname><given-names>M.</given-names></name><name><surname>Ye</surname><given-names>Z.</given-names></name><name><surname>Kolesar</surname><given-names>J. M.</given-names></name><name><surname>Hebbring</surname><given-names>S. J.</given-names></name><name><surname>Lin</surname><given-names>S. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Opportunities for Drug Repositioning from Phenome-wide Association Studies</article-title>. <source>Nat. Biotechnol.</source>
<volume>33</volume> (<issue>4</issue>), <fpage>342</fpage>–<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3183</pub-id>
<pub-id pub-id-type="pmid">25850054</pub-id></mixed-citation>
    </ref>
    <ref id="B48">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reay</surname><given-names>W. R.</given-names></name><name><surname>Cairns</surname><given-names>M. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Advancing the Use of Genome-wide Association Studies for Drug Repurposing</article-title>. <source>Nat. Rev. Genet.</source>
<volume>22</volume> (<issue>10</issue>), <fpage>658</fpage>–<lpage>671</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-021-00387-z</pub-id>
<pub-id pub-id-type="pmid">34302145</pub-id></mixed-citation>
    </ref>
    <ref id="B49">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reel</surname><given-names>P. S.</given-names></name><name><surname>Reel</surname><given-names>S.</given-names></name><name><surname>Pearson</surname><given-names>E.</given-names></name><name><surname>Trucco</surname><given-names>E.</given-names></name><name><surname>Jefferson</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Using Machine Learning Approaches for Multi-Omics Data Analysis: A Review</article-title>. <source>Biotechnol. Adv.</source>
<volume>49</volume>, <fpage>107739</fpage>. <pub-id pub-id-type="doi">10.1016/j.biotechadv.2021.107739</pub-id>
<pub-id pub-id-type="pmid">33794304</pub-id></mixed-citation>
    </ref>
    <ref id="B50">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>J. R.</given-names></name><name><surname>Denny</surname><given-names>J. C.</given-names></name><name><surname>Roden</surname><given-names>D. M.</given-names></name><name><surname>Van Driest</surname><given-names>S. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records</article-title>. <source>Clin. Transl. Sci.</source>
<volume>11</volume> (<issue>2</issue>), <fpage>112</fpage>–<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1111/cts.12522</pub-id>
<pub-id pub-id-type="pmid">29148204</pub-id></mixed-citation>
    </ref>
    <ref id="B51">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanseau</surname><given-names>P.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name><name><surname>Barnes</surname><given-names>M. R.</given-names></name><name><surname>Pastinen</surname><given-names>T.</given-names></name><name><surname>Richards</surname><given-names>J. B.</given-names></name><name><surname>Cardon</surname><given-names>L. R.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Use of Genome-wide Association Studies for Drug Repositioning</article-title>. <source>Nat. Biotechnol.</source>
<volume>30</volume> (<issue>4</issue>), <fpage>317</fpage>–<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2151</pub-id>
<pub-id pub-id-type="pmid">22491277</pub-id></mixed-citation>
    </ref>
    <ref id="B52">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarayloo</surname><given-names>F.</given-names></name><name><surname>Dion</surname><given-names>P. A.</given-names></name><name><surname>Rouleau</surname><given-names>G. A.</given-names></name></person-group> (<year>2019</year>). <article-title>MEIS1 and Restless Legs Syndrome: A Comprehensive Review</article-title>. <source>Front. Neurol.</source>
<volume>10</volume>, <fpage>935</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2019.00935</pub-id>
<pub-id pub-id-type="pmid">31551905</pub-id></mixed-citation>
    </ref>
    <ref id="B53">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Glicksberg</surname><given-names>B. S.</given-names></name><name><surname>Badgeley</surname><given-names>M. A.</given-names></name><name><surname>Johnson</surname><given-names>K. W.</given-names></name><name><surname>Dudley</surname><given-names>J. T.</given-names></name></person-group> (<year>2021</year>). <article-title>Pleiotropic Variability Score: A Genome Interpretation Metric to Quantify Phenomic Associations of Genomic Variants</article-title>. <source>bioRxiv</source>. <pub-id pub-id-type="doi">10.1101/2021.07.18.452819</pub-id>
</mixed-citation>
    </ref>
    <ref id="B54">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Glicksberg</surname><given-names>B. S.</given-names></name><name><surname>Hodos</surname><given-names>R.</given-names></name><name><surname>Johnson</surname><given-names>K. W.</given-names></name><name><surname>Badgeley</surname><given-names>M. A.</given-names></name><name><surname>Readhead</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>Systematic Analyses of Drugs and Disease Indications in RepurposeDB Reveal Pharmacological, Biological and Epidemiological Factors Influencing Drug Repositioning</article-title>. <source>Briefings Bioinforma.</source>
<volume>19</volume> (<issue>4</issue>), <fpage>656</fpage>–<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbw136</pub-id>
</mixed-citation>
    </ref>
    <ref id="B55">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Johnson</surname><given-names>K. W.</given-names></name><name><surname>Glicksberg</surname><given-names>B. S.</given-names></name><name><surname>Dudley</surname><given-names>J. T.</given-names></name><name><surname>Sengupta</surname><given-names>P. P.</given-names></name></person-group> (<year>2018</year>). <article-title>Machine Learning in Cardiovascular Medicine: Are We There yet?</article-title>
<source>Heart</source>
<volume>104</volume> (<issue>14</issue>), <fpage>1156</fpage>–<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2017-311198</pub-id>
<pub-id pub-id-type="pmid">29352006</pub-id></mixed-citation>
    </ref>
    <ref id="B56">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Readhead</surname><given-names>B.</given-names></name><name><surname>T. Dudley</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Computational and Experimental Advances in Drug Repositioning for Accelerated Therapeutic Stratification</article-title>. <source>Ctmc</source>
<volume>15</volume> (<issue>1</issue>), <fpage>5</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.2174/1568026615666150112103510</pub-id>
</mixed-citation>
    </ref>
    <ref id="B57">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shameer</surname><given-names>K.</given-names></name><name><surname>Tripathi</surname><given-names>L. P.</given-names></name><name><surname>Kalari</surname><given-names>K. R.</given-names></name><name><surname>Dudley</surname><given-names>J. T.</given-names></name><name><surname>Sowdhamini</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Interpreting Functional Effects of Coding Variants: Challenges in Proteome-Scale Prediction, Annotation and Assessment</article-title>. <source>Brief. Bioinform</source>
<volume>17</volume> (<issue>5</issue>), <fpage>841</fpage>–<lpage>862</lpage>. <pub-id pub-id-type="doi">10.1093/bib/bbv084</pub-id>
<pub-id pub-id-type="pmid">26494363</pub-id></mixed-citation>
    </ref>
    <ref id="B58">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheils</surname><given-names>T. K.</given-names></name><name><surname>Mathias</surname><given-names>S. L.</given-names></name><name><surname>Kelleher</surname><given-names>K. J.</given-names></name><name><surname>Siramshetty</surname><given-names>V. B.</given-names></name><name><surname>Nguyen</surname><given-names>D.-T.</given-names></name><name><surname>Bologa</surname><given-names>C. G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>TCRD and Pharos 2021: Mining the Human Proteome for Disease Biology</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D1334</fpage>–<lpage>D1346</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa993</pub-id>
<pub-id pub-id-type="pmid">33156327</pub-id></mixed-citation>
    </ref>
    <ref id="B59">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiloh</surname><given-names>Y.</given-names></name><name><surname>Ziv</surname><given-names>Y.</given-names></name></person-group> (<year>2013</year>). <article-title>The ATM Protein Kinase: Regulating the Cellular Response to Genotoxic Stress, and More</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source>
<volume>14</volume> (<issue>4</issue>), <fpage>197</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3546</pub-id>
</mixed-citation>
    </ref>
    <ref id="B60">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>I.</given-names></name><name><surname>Verma</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Jere</surname><given-names>A.</given-names></name><name><surname>Anamika</surname><given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Multi-omics Data Integration, Interpretation, and its Application</article-title>. <source>Bioinform Biol. Insights</source>
<volume>14</volume>, <fpage>117793221989905</fpage>. <pub-id pub-id-type="doi">10.1177/1177932219899051</pub-id>
</mixed-citation>
    </ref>
    <ref id="B61">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D.</given-names></name><name><surname>Gable</surname><given-names>A. L.</given-names></name><name><surname>Nastou</surname><given-names>K. C.</given-names></name><name><surname>Lyon</surname><given-names>D.</given-names></name><name><surname>Kirsch</surname><given-names>R.</given-names></name><name><surname>Pyysalo</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The STRING Database in 2021: Customizable Protein-Protein Networks, and Functional Characterization of User-Uploaded Gene/measurement Sets</article-title>. <source>Nucleic Acids Res.</source>
<volume>49</volume> (<issue>D1</issue>), <fpage>D605</fpage>–<lpage>D612</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkaa1074</pub-id>
<pub-id pub-id-type="pmid">33237311</pub-id></mixed-citation>
    </ref>
    <ref id="B62">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Gong</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Promethazine Inhibits Proliferation and Promotes Apoptosis in Colorectal Cancer Cells by Suppressing the PI3K/AKT Pathway</article-title>. <source>Biomed. Pharmacother.</source>
<volume>143</volume>, <fpage>112174</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112174</pub-id>
<pub-id pub-id-type="pmid">34560542</pub-id></mixed-citation>
    </ref>
    <ref id="B63">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>R.</given-names></name><name><surname>Majumdar</surname><given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>A New Prospect for the Treatment of Nephrotic Syndrome Based on Network Pharmacology Analysis</article-title>. <source>Curr. Res. Physiology</source>
<volume>5</volume>, <fpage>36</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.crphys.2021.12.004</pub-id>
</mixed-citation>
    </ref>
    <ref id="B64">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wears</surname><given-names>R. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Standardisation and its Discontents</article-title>. <source>Cogn. Tech. Work</source>
<volume>17</volume> (<issue>1</issue>), <fpage>89</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s10111-014-0299-6</pub-id>
</mixed-citation>
    </ref>
    <ref id="B65">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissler</surname><given-names>E. H.</given-names></name><name><surname>Naumann</surname><given-names>T.</given-names></name><name><surname>Andersson</surname><given-names>T.</given-names></name><name><surname>Ranganath</surname><given-names>R.</given-names></name><name><surname>Elemento</surname><given-names>O.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>The Role of Machine Learning in Clinical Research: Transforming the Future of Evidence Generation</article-title>. <source>Trials</source>
<volume>22</volume> (<issue>1</issue>), <fpage>537</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-021-05489-x</pub-id>
<pub-id pub-id-type="pmid">34399832</pub-id></mixed-citation>
    </ref>
    <ref id="B66">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wijetunga</surname><given-names>I.</given-names></name><name><surname>McVeigh</surname><given-names>L. E.</given-names></name><name><surname>Charalambous</surname><given-names>A.</given-names></name><name><surname>Antanaviciute</surname><given-names>A.</given-names></name><name><surname>Carr</surname><given-names>I. M.</given-names></name><name><surname>Nair</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review</article-title>. <source>Cancers</source>
<volume>12</volume> (<issue>10</issue>), <fpage>2817</fpage>. <pub-id pub-id-type="doi">10.3390/cancers12102817</pub-id>
</mixed-citation>
    </ref>
    <ref id="B67">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Review of Drug Repositioning Approaches and Resources</article-title>. <source>Int. J. Biol. Sci.</source>
<volume>14</volume> (<issue>10</issue>), <fpage>1232</fpage>–<lpage>1244</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.24612</pub-id>
<pub-id pub-id-type="pmid">30123072</pub-id></mixed-citation>
    </ref>
    <ref id="B68">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zada</surname><given-names>D.</given-names></name><name><surname>Sela</surname><given-names>Y.</given-names></name><name><surname>Matosevich</surname><given-names>N.</given-names></name><name><surname>Monsonego</surname><given-names>A.</given-names></name><name><surname>Lerer-Goldshtein</surname><given-names>T.</given-names></name><name><surname>Nir</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Parp1 Promotes Sleep, Which Enhances DNA Repair in Neurons</article-title>. <source>Mol. Cell</source>
<volume>81</volume> (<issue>24</issue>), <fpage>4979</fpage>–<lpage>4993</lpage>. <comment>e7</comment>. <pub-id pub-id-type="doi">10.1016/j.molcel.2021.10.026</pub-id>
<pub-id pub-id-type="pmid">34798058</pub-id></mixed-citation>
    </ref>
    <ref id="B69">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>So</surname><given-names>H.-C.</given-names></name></person-group> (<year>2022</year>). <article-title>Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach</article-title>. <source>Pharmaceutics</source>
<volume>14</volume> (<issue>2</issue>), <fpage>234</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics14020234</pub-id>
<pub-id pub-id-type="pmid">35213968</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
